- The clinical efficacy and safety of naftopidil 75 mg on benign prostatic hyperplasia patients with moderate or severe urinary disturbance - (https://pubmed.ncbi.nlm.nih.gov/19462821/ )
- Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia - (https://pubmed.ncbi.nlm.nih.gov/30306544/ )
- Safety profile of medication used during pregnancy: results of a multinational European study - (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518438/ )
- Outcomes and complications of naftopidil versus tamsulosin for elderly men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review and meta-analysis - (https://pubmed.ncbi.nlm.nih.gov/34189764/ )
Information about Naftopidil
Generic Name : NaftopidilUp-to-date prescription details regarding Naftopidil are provided here.
Pronunciation : Naf-top-i-dil
Learn the correct pronunciation of the Naftopidil, understand it's uses, recommended dosages, its indications, how to take, when to take, when not to take, side effects, special precautions, warnings and its and its storage instructions.You will also find a list of the medication's International and Indian brand or trade names, as well as its pricing information. For verification of the information presented on this page or for additional clarifications, it's advisable to consult your doctor.
Therapeutic Classification : BPH Agents
Trade Names/Brand Names of Naftopidil
India :
Overview of Naftopidil
• Naftopidil is a selective α1-adrenergic receptor antagonist or alpha blocker used to treat benign hyperplasia of prostate with, lower urinary tract symptoms.Why is Naftopidil Prescribed? (Indications)
Naftopidil is a selective α1-adrenergic receptor antagonist or alpha blocker.Naftopidil is prescribed in Japan for the treatment of benign prostatic hyperplasia (BPH) and benign prostatic obstruction, associated with lower urinary tract symptoms (LUTS), hypertension, cardiac valve disease, and distal ureteral stones.
Further large-scale, randomized, placebo-controlled studies need to be done to see if the naftopidil efficacy and safety data that is applicable to Japanese can be extended to white, black and Hispanic men having LUTS/BPH in western countries.